74.520.40% ( +0.30 )
Delay Closed: Nov 17, 15:00:00Valuation
Current ValuationThe current P/E ratio is -216.10, below the reasonable range, cheaper than 95.9% of the time in the past 3 years, and the industry ranks 27/27, the industry Median 46.32.
-216.1xP/E
¥74.22Stock price
¥-0.34Earnings per share
-216.1xP/E
Stock price¥74.22Earnings per share¥-0.34
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -30.36x
- Typical range
- -81.20x–-15.54x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 46.32x
012243648
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 46.32x
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
300347SZTigermed | -99.25x | 71.25% | ¥40.16B |
688114SHMGI | -119.84x | 70.26% | ¥22.74B |
688202SHMedicilon | -216.10x | -- | ¥9.97B |
688068SHHotgen | -19.98x | -- | ¥5.98B |
603108SHRunda Medical | -10.32x | 137.36% | ¥5.77B |
300463SZmaccura | -158.72x | 133.73% | ¥5.22B |
688238SHOBiO Tech | -19.17x | 18.92% | ¥4.20B |
301096SZBio-S | -23.16x | -- | ¥4.13B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
